Logo image of SHPH

SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Fundamental Analysis

NASDAQ:SHPH - Nasdaq - US8256933024 - Common Stock - Currency: USD

0.6701  -0.04 (-5.62%)

Premarket: 0.7 +0.03 (+4.46%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SHPH. SHPH was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of SHPH have multiple concerns. SHPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year SHPH has reported negative net income.
In the past year SHPH has reported a negative cash flow from operations.
SHPH Yearly Net Income VS EBIT VS OCF VS FCFSHPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

The Return On Assets of SHPH (-110.78%) is worse than 78.05% of its industry peers.
The Return On Equity of SHPH (-162.56%) is worse than 66.19% of its industry peers.
Industry RankSector Rank
ROA -110.78%
ROE -162.56%
ROIC N/A
ROA(3y)-113.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SHPH Yearly ROA, ROE, ROICSHPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2020 2021 2022 2023 0 100 -100

1.3 Margins

SHPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SHPH Yearly Profit, Operating, Gross MarginsSHPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2020 2021 2022 2023

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, SHPH has more shares outstanding
The debt/assets ratio for SHPH is higher compared to a year ago.
SHPH Yearly Shares OutstandingSHPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2020 2021 2022 2023 10M 20M 30M 40M
SHPH Yearly Total Debt VS Total AssetsSHPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -5.21, we must say that SHPH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.21, SHPH is doing worse than 63.54% of the companies in the same industry.
SHPH has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
SHPH's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. SHPH outperforms 40.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -5.21
ROIC/WACCN/A
WACCN/A
SHPH Yearly LT Debt VS Equity VS FCFSHPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2020 2021 2022 2023 0 2M -2M 4M -4M 6M

2.3 Liquidity

A Current Ratio of 5.37 indicates that SHPH has no problem at all paying its short term obligations.
With a Current ratio value of 5.37, SHPH perfoms like the industry average, outperforming 57.17% of the companies in the same industry.
SHPH has a Quick Ratio of 5.37. This indicates that SHPH is financially healthy and has no problem in meeting its short term obligations.
SHPH's Quick ratio of 5.37 is in line compared to the rest of the industry. SHPH outperforms 58.05% of its industry peers.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 5.37
SHPH Yearly Current Assets VS Current LiabilitesSHPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2020 2021 2022 2023 2M 4M 6M 8M

0

3. Growth

3.1 Past

The earnings per share for SHPH have decreased strongly by -89.70% in the last year.
EPS 1Y (TTM)-89.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SHPH Yearly Revenue VS EstimatesSHPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2020 2021 2022 2023
SHPH Yearly EPS VS EstimatesSHPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SHPH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SHPH Price Earnings VS Forward Price EarningsSHPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SHPH Per share dataSHPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for SHPH!.
Industry RankSector Rank
Dividend Yield N/A

SHUTTLE PHARMACEUTICALS HOLD

NASDAQ:SHPH (2/5/2025, 8:26:59 PM)

Premarket: 0.7 +0.03 (+4.46%)

0.6701

-0.04 (-5.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners1.72%
Inst Owner Change0%
Ins Owners41.62%
Ins Owner Change0%
Market Cap2.45M
AnalystsN/A
Price TargetN/A
Short Float %0.33%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.78%
ROE -162.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 279.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 5.37
Altman-Z -5.21
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-89.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70.75%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-130.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-106.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.95%
OCF growth 3YN/A
OCF growth 5YN/A